idoxifene has not yet been approved in the US, EU or Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


idoxifene studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
223030/15 and 223030/16 III A combined report for protocols SB223030/015 and SB223030/016: a randomized, double-blind, placebo-controlled trial of the effect of idoxifene in the prevention of bone loss in early postmenopausal women and a randomized, double-blind, placebo-controlled trial of the effect of idoxifene in the prevention of osteoporosis in postmenopausal women with low bone mineral density
223030/059 II A Multicentre, Randomised, Double-Blind, Study of Idoxifene 40mg/dayversus Tamoxifene 20mg/day as First-Line Hormonal Therapy in Postmenopausal Women with Metastatic Breast Cancer